Free Water in White Matter Differentiates MCI and AD From Control Subjects

Matthieu Dumont1, Maggie Roy1,2, Pierre-Marc Jodoin1,3

  • 1Imeka Solutions, Inc., Sherbrooke, QC, Canada.

Insights

Free water (FW) imaging detects neuroinflammation in mild cognitive impairment (MCI) and Alzheimer's disease (AD). This novel FW measure, excluding white matter damage, distinguishes healthy individuals from MCI and AD patients.

Area of Science:

  • Neuroimaging
  • Neurology
  • Biomedical Engineering

Background:

  • Neuroinflammation is implicated in neurological diseases like mild cognitive impairment (MCI) and Alzheimer's disease (AD).
  • Free water (FW) imaging, derived from diffusion MRI, shows sensitivity to neuroinflammation.

Purpose of the Study:

  • To develop a simple, clinically translatable whole-brain FW measure for neurological disease research.
  • To investigate if FW measures in a "safe" white matter (WM) mask can differentiate diagnostic groups along the AD continuum.

Main Methods:

  • A "safe" white matter (WM) mask was used, excluding gray matter/cerebrospinal fluid (CSF) partial volume effects.
  • FW measures were computed across the whole WM, both including and excluding white matter hyperintensities (WMHs).
  • Data from 81 normal controls (NC), 103 MCI, and 42 AD subjects from ADNI databases were analyzed.

Main Results:

  • MCI and AD groups exhibited significantly higher FW measures compared to NC, even after removing partial volume contamination.
  • These significant findings were maintained when white matter hyperintensities (WMHs) were excluded, indicating FW is not solely a byproduct of WMHs.
  • The developed FW measures show potential for differentiating healthy individuals from those with MCI and AD.

Conclusions:

  • The novel, simple FW measures are sensitive to changes along the AD continuum.
  • These FW measures are not confounded by white matter hyperintensities.
  • This approach may serve as a valuable tool for understanding inflammation-associated edema and aiding diagnosis in clinical trials.